Fecal Microbiota Transplantation: History, Procedure and Regulatory Considerations
Presse Med. 2023 Nov 7:104204. doi: 10.1016/j.lpm.2023.104204. Online ahead of print.ABSTRACTFecal microbiota transplantation (FMT) is a medical treatment which involves the transfer of feces from a healthy donor to a recipient to restore the balance of gut microbiota and improve clinical outcomes. FMT has gained recognition in recent years due to its effectiveness in treating recurrent Clostridioides difficile infections (rCDI) and other gastrointestinal disorders. Additionally, it has been studied as an intervention for some other conditions, like inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). This ...
Source: Presse Medicale - November 9, 2023 Category: General Medicine Authors: Thanush D M P Venkatesh Source Type: research
Prevention of neurovascular complications in children with Sickle Cell Disease in the real-world setting: what adult medicine physicians should know
Presse Med. 2023 Nov 6:104201. doi: 10.1016/j.lpm.2023.104201. Online ahead of print.ABSTRACTNeurovascular complications represent one of the most detrimental manifestations of Sickle Cell Disease (SCD), affecting many patients since infancy. They include overt stroke, silent cerebral infarcts and neurocognitive disorders. In fact, neurodevelopment can be impaired in children resulting in cognitive dysfunction in adults with SCD. This review is meant to resume the most recent guidelines about the prevention of SCD neurovascular complications and to highlight the open challenges in their implementation. Transcranial Doppler...
Source: Presse Medicale - November 8, 2023 Category: General Medicine Authors: Giulia Reggiani Maria Paola Boaro Raffaella Colombatti Source Type: research
Sickle Cell Disease and Pregnancy
Presse Med. 2023 Nov 6:104203. doi: 10.1016/j.lpm.2023.104203. Online ahead of print.ABSTRACTPregnancy is a particularly risky period in the life of patients with sickle cell disease (SCD). Physiological changes during pregnancy increase the risk of vaso-occlusive crises (VOC), acute chest syndrome, venous thromboembolic events, and infections. This concerns haemoglobin (Hb) S/C and S/β+-thalassemia patients as much than S/S or S/β0-thalassemia patients. SCD also increases the risk of obstetrical complications, such as preeclampsia, in utero foetal death, preterm delivery mostly induced, and intrauterine growth restricti...
Source: Presse Medicale - November 8, 2023 Category: General Medicine Authors: Julie Carrara Anoosha Habibi Alexandra Benachi Geoffrey Cheminet Source Type: research
Prevention of neurovascular complications in children with Sickle Cell Disease in the real-world setting: what adult medicine physicians should know
Presse Med. 2023 Nov 6:104201. doi: 10.1016/j.lpm.2023.104201. Online ahead of print.ABSTRACTNeurovascular complications represent one of the most detrimental manifestations of Sickle Cell Disease (SCD), affecting many patients since infancy. They include overt stroke, silent cerebral infarcts and neurocognitive disorders. In fact, neurodevelopment can be impaired in children resulting in cognitive dysfunction in adults with SCD. This review is meant to resume the most recent guidelines about the prevention of SCD neurovascular complications and to highlight the open challenges in their implementation. Transcranial Doppler...
Source: Presse Medicale - November 8, 2023 Category: General Medicine Authors: Giulia Reggiani Maria Paola Boaro Raffaella Colombatti Source Type: research
Sickle Cell Disease and Pregnancy
Presse Med. 2023 Nov 6:104203. doi: 10.1016/j.lpm.2023.104203. Online ahead of print.ABSTRACTPregnancy is a particularly risky period in the life of patients with sickle cell disease (SCD). Physiological changes during pregnancy increase the risk of vaso-occlusive crises (VOC), acute chest syndrome, venous thromboembolic events, and infections. This concerns haemoglobin (Hb) S/C and S/β+-thalassemia patients as much than S/S or S/β0-thalassemia patients. SCD also increases the risk of obstetrical complications, such as preeclampsia, in utero foetal death, preterm delivery mostly induced, and intrauterine growth restricti...
Source: Presse Medicale - November 8, 2023 Category: General Medicine Authors: Julie Carrara Anoosha Habibi Alexandra Benachi Geoffrey Cheminet Source Type: research
End-stage heart failure: the future of heart transplant and artificial heart
Presse Med. 2023 Oct 26:104191. doi: 10.1016/j.lpm.2023.104191. Online ahead of print.ABSTRACTIn the last decades, outcomes significantly improved for both heart transplantation and LVAD. Heart transplantation remains the gold standard for the treatment of end stage heart failure and will remain for many years to come. The most relevant limitations are the lack of grafts and the effects of long-term immunosuppressive therapy that involve infectious, cancerous and metabolic complications despite advances in immunosuppression management. Mechanical circulatory support has an irreplaceable role in the treatment of end-staged ...
Source: Presse Medicale - October 28, 2023 Category: General Medicine Authors: Karl Bounader Erwan Fl écher Source Type: research
Electrical therapies in heart failure: evolving technologies and indications
Presse Med. 2023 Oct 26:104192. doi: 10.1016/j.lpm.2023.104192. Online ahead of print.ABSTRACTDevice therapy for heart failure has rapidly evolved over 2 decades. Theknowledge of indications, assessment lead and device technology has expanded to include CRT, leadless pacing and conduction system pacing such as His bundle and left bundle branch area pacing. But there is still a lack of evidence for these new technologies as well as for common indications such as atrial fibrillation and upgrading from a previous device. The role of personlized medicine will become increasingly important when selecting candidates for CRT, pri...
Source: Presse Medicale - October 28, 2023 Category: General Medicine Authors: Cecilia Linde Source Type: research
End-stage heart failure: the future of heart transplant and artificial heart
Presse Med. 2023 Oct 26:104191. doi: 10.1016/j.lpm.2023.104191. Online ahead of print.ABSTRACTIn the last decades, outcomes significantly improved for both heart transplantation and LVAD. Heart transplantation remains the gold standard for the treatment of end stage heart failure and will remain for many years to come. The most relevant limitations are the lack of grafts and the effects of long-term immunosuppressive therapy that involve infectious, cancerous and metabolic complications despite advances in immunosuppression management. Mechanical circulatory support has an irreplaceable role in the treatment of end-staged ...
Source: Presse Medicale - October 28, 2023 Category: General Medicine Authors: Karl Bounader Erwan Fl écher Source Type: research
Electrical therapies in heart failure: evolving technologies and indications
Presse Med. 2023 Oct 26:104192. doi: 10.1016/j.lpm.2023.104192. Online ahead of print.ABSTRACTDevice therapy for heart failure has rapidly evolved over 2 decades. Theknowledge of indications, assessment lead and device technology has expanded to include CRT, leadless pacing and conduction system pacing such as His bundle and left bundle branch area pacing. But there is still a lack of evidence for these new technologies as well as for common indications such as atrial fibrillation and upgrading from a previous device. The role of personlized medicine will become increasingly important when selecting candidates for CRT, pri...
Source: Presse Medicale - October 28, 2023 Category: General Medicine Authors: Cecilia Linde Source Type: research
End-stage heart failure: the future of heart transplant and artificial heart
Presse Med. 2023 Oct 26:104191. doi: 10.1016/j.lpm.2023.104191. Online ahead of print.ABSTRACTIn the last decades, outcomes significantly improved for both heart transplantation and LVAD. Heart transplantation remains the gold standard for the treatment of end stage heart failure and will remain for many years to come. The most relevant limitations are the lack of grafts and the effects of long-term immunosuppressive therapy that involve infectious, cancerous and metabolic complications despite advances in immunosuppression management. Mechanical circulatory support has an irreplaceable role in the treatment of end-staged ...
Source: Presse Medicale - October 28, 2023 Category: General Medicine Authors: Karl Bounader Erwan Fl écher Source Type: research
Electrical therapies in heart failure: evolving technologies and indications
Presse Med. 2023 Oct 26:104192. doi: 10.1016/j.lpm.2023.104192. Online ahead of print.ABSTRACTDevice therapy for heart failure has rapidly evolved over 2 decades. Theknowledge of indications, assessment lead and device technology has expanded to include CRT, leadless pacing and conduction system pacing such as His bundle and left bundle branch area pacing. But there is still a lack of evidence for these new technologies as well as for common indications such as atrial fibrillation and upgrading from a previous device. The role of personlized medicine will become increasingly important when selecting candidates for CRT, pri...
Source: Presse Medicale - October 28, 2023 Category: General Medicine Authors: Cecilia Linde Source Type: research
End-stage heart failure: the future of heart transplant and artificial heart
Presse Med. 2023 Oct 26:104191. doi: 10.1016/j.lpm.2023.104191. Online ahead of print.ABSTRACTIn the last decades, outcomes significantly improved for both heart transplantation and LVAD. Heart transplantation remains the gold standard for the treatment of end stage heart failure and will remain for many years to come. The most relevant limitations are the lack of grafts and the effects of long-term immunosuppressive therapy that involve infectious, cancerous and metabolic complications despite advances in immunosuppression management. Mechanical circulatory support has an irreplaceable role in the treatment of end-staged ...
Source: Presse Medicale - October 28, 2023 Category: General Medicine Authors: Karl Bounader Erwan Fl écher Source Type: research
Electrical therapies in heart failure: evolving technologies and indications
Presse Med. 2023 Oct 26:104192. doi: 10.1016/j.lpm.2023.104192. Online ahead of print.ABSTRACTDevice therapy for heart failure has rapidly evolved over 2 decades. Theknowledge of indications, assessment lead and device technology has expanded to include CRT, leadless pacing and conduction system pacing such as His bundle and left bundle branch area pacing. But there is still a lack of evidence for these new technologies as well as for common indications such as atrial fibrillation and upgrading from a previous device. The role of personlized medicine will become increasingly important when selecting candidates for CRT, pri...
Source: Presse Medicale - October 28, 2023 Category: General Medicine Authors: Cecilia Linde Source Type: research
End-stage heart failure: the future of heart transplant and artificial heart
Presse Med. 2023 Oct 26:104191. doi: 10.1016/j.lpm.2023.104191. Online ahead of print.ABSTRACTIn the last decades, outcomes significantly improved for both heart transplantation and LVAD. Heart transplantation remains the gold standard for the treatment of end stage heart failure and will remain for many years to come. The most relevant limitations are the lack of grafts and the effects of long-term immunosuppressive therapy that involve infectious, cancerous and metabolic complications despite advances in immunosuppression management. Mechanical circulatory support has an irreplaceable role in the treatment of end-staged ...
Source: Presse Medicale - October 28, 2023 Category: General Medicine Authors: Karl Bounader Erwan Fl écher Source Type: research
Electrical therapies in heart failure: evolving technologies and indications
Presse Med. 2023 Oct 26:104192. doi: 10.1016/j.lpm.2023.104192. Online ahead of print.ABSTRACTDevice therapy for heart failure has rapidly evolved over 2 decades. Theknowledge of indications, assessment lead and device technology has expanded to include CRT, leadless pacing and conduction system pacing such as His bundle and left bundle branch area pacing. But there is still a lack of evidence for these new technologies as well as for common indications such as atrial fibrillation and upgrading from a previous device. The role of personlized medicine will become increasingly important when selecting candidates for CRT, pri...
Source: Presse Medicale - October 28, 2023 Category: General Medicine Authors: Cecilia Linde Source Type: research
